Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

BACKGROUND: Dosing schemes of pembrolizumab (anti-programmed cell death protein 1 monoclonal antibody) are solely based on pharmacokinetic (PK) modelling derived from phase I–III trials. The current study aimed to determine factors affecting PK and its relationship with clinical outcome in the real-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Hurkmans, Daan P., Sassen, Sebastiaan D.T., de Joode, Karlijn, Putter, Lisanne, Basak, Edwin A., Wijkhuijs, Annemarie J.M., Joerger, Markus, Debets, Reno, Koch, Birgit C.P., Van der Leest, Cor H., Schreurs, Marco W.J., van der Veldt, Astrid A.M., Aerts, Joachim G.J.V., Mathijssen, Ron H.J., Koolen, Stijn L.W.
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2021
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183294/
https://ncbi.nlm.nih.gov/pubmed/34088739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002344
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky